[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657986":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":30,"studyPopulation":20,"armGroups":31,"interventions":43,"overallOfficials":20,"centralContacts":57,"locations":67,"responsibleParty":91,"collaborators":95,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":20,"eligibilityCriteria":104,"healthyVolunteers":101,"sex":105,"minAge":106,"maxAge":20,"enrollmentInfo":107,"targetDuration":20,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":70,"whyStopped":20,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"Indiana University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Change in GC soma density (cells\u002Fmm²)","Change in ganglion cell (GC) soma density during treatment with timolol versus netarsudil (Rhopressa)","Baseline, 6 months, and 12 months",[14,17],{"measure":15,"description":16,"timeFrame":12},"Changes in GC soma counts (number of cells)","Changes in ganglion cell (GC) soma counts during treatment with timolol versus netarsudil (Rhopressa)",{"measure":18,"description":19,"timeFrame":12},"Changes in GCL thickness (micrometers (µm))","Changes in ganglion cell layer (GCL) thickness during treatment with timolol versus netarsudil (Rhopressa)",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":6,"observationalModel":20,"timePerspective":20,"maskingInfo":24},"RANDOMIZED","CROSSOVER",{"masking":25,"maskingDescription":26,"whoMasked":27},"DOUBLE","This is a investigator-masked study. Randomization will occur from an unmasked key personnel member on the study. The principal investigator and other key members of the study will be masked. Unmasked personnel maintain the randomization schedule and manage drug distribution, but have no role in clinical evaluations, AO-OCT image acquisition, ganglion cell counting, or outcome data analysis.",[28,29],"INVESTIGATOR","OUTCOMES_ASSESSOR","Glaucoma is a chronic, progressive optic neuropathy characterized by functional and structural alterations, specifically the degeneration and loss of retinal ganglion cells (RGCs). Currently, the main modifiable factor for intervention is aimed at lowering intraocular pressure (IOP). While IOP reduction slows disease progression, it does not halt neurodegeneration. Rho kinase (ROCK) inhibitors have been reported to provide benefit in neurodegenerative diseases. Netarsudil ophthalmic solution (Rhopressa) is a ROCK inhibitor approved for the treatment and management of open-angle glaucoma that lowers IOP and has reported protective effects on neural tissue. However, previous attempts to illustrate true cell loss or protection using clinical instrumentation have not demonstrated an effect to date.\n\nHigh-resolution retinal imaging based on adaptive optics optical coherence tomography (AO-OCT) enables direct visualization, tracking, and quantification of individual ganglion cell layer (GCL) somas in the living human eye. Leveraging the unique imaging capabilities and extraordinary sensitivity of ultra-high-speed AO-OCT, this study will test the hypothesis that treatment with netarsudil is more effective at reducing glaucomatous ganglion cell loss while producing comparable intraocular pressure reduction to that of the comparator.\n\nThis prospective, randomized, investigator-masked, cross-over pilot study will compare RGC survival rates between two treatment groups (Rhopressa and Timolol). Thirteen subjects with open-angle glaucoma will be recruited. Following a screening assessment and medication washout period based on drug class, eligible subjects are randomized 1:1 into two age-matched cohorts:\n\n* Cohort 1: Receives Rhopressa (one drop once at night) for 6 months, then crosses over to receive Timolol 0.25% (one drop twice a day) for 6 months.\n* Cohort 2: Receives Timolol 0.25% (one drop twice a day) for 6 months, then crosses over to receive Rhopressa (one drop once at night) for 6 months.\n\nAt Visit 2 (baseline), Visit 4 (6 months), and Visit 6 (12 months), subjects undergo imaging using the Indiana AO-OCT system along with Goldmann applanation tonometry, standard clinical OCT, and OCT-guided microperimetry (MP-3). AO-OCT imaging is performed at the same retinal regions surrounding arcuate defects to enable longitudinal cellular-level analysis. Primary and secondary endpoints evaluate differences in the rate of change of RGC soma density, individual RGC counts, and GCL thickness between treatment periods.",[32,39],{"label":33,"type":34,"description":35,"interventionNames":36},"Rhopressa first, then Timolol","EXPERIMENTAL","Participants will instill netarsudil 0.02% (Rhopressa) ophthalmic solution (1 drop in the study eye once daily in the evening) for the first 6 months (Months 0-6). At the Month 6 visit, participants will cross over to instill timolol maleate 0.25% ophthalmic solution (1 drop in the study eye twice daily) for the remaining 6 months (Months 6-12).",[37,38],"Drug: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]","Drug: Timolol Maleate 0.25% Ophthalmic Solution",{"label":40,"type":34,"description":41,"interventionNames":42},"Timolol first, then Rhopressa","Participants will instill timolol maleate 0.25% ophthalmic solution (1 drop in the study eye twice daily) for the first 6 months (Months 0-6). At the Month 6 visit, participants will cross over to instill netarsudil 0.02% (Rhopressa) ophthalmic solution (1 drop in the study eye once daily in the evening) for the remaining 6 months (Months 6-12).",[37,38],[44,51],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"DRUG","Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]","Netarsudil ophthalmic solution (Rhopressa) is an FDA-approved Rho kinase inhibitor indicated for the treatment of ocular hypertension and open-angle glaucoma. In this study, participants will instill 1 drop of netarsudil 0.02% ophthalmic solution in the study eye once daily in the evening for 6 months.",[33,40],[50],"Rhopressa",{"type":45,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"Timolol Maleate 0.25% Ophthalmic Solution","Timolol maleate ophthalmic solution is an FDA-approved non-selective beta-adrenergic receptor blocking agent indicated for the treatment of ocular hypertension and open-angle glaucoma. In this study, participants will instill 1 drop of timolol maleate 0.25% ophthalmic solution in the study eye twice daily (in the morning and evening) for 6 months.",[33,40],[56],"Timoptic",[58,63],{"name":59,"role":60,"phone":61,"phoneExt":20,"email":62},"Brett J King, OD, FAAO, Dipl AAO (Glaucoma)","CONTACT","(812) 855-1344","kingbrj@iu.edu",{"name":64,"role":60,"phone":65,"phoneExt":20,"email":66},"Kaitlyn M Asher, CCRC, BS","2194067487","kamasher@iu.edu",[68],{"facility":69,"status":70,"city":71,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"Indiana University School Of Optometry","RECRUITING","Bloomington","Indiana","47405","United States","US",{"type":77,"coordinates":78},"Point",[79,80],-86.52639,39.16533,{"lat":80,"lon":79},[83,85,86,89],{"name":84,"role":60,"phone":61,"phoneExt":20,"email":62},"Brett J King, OD, FAAO, Dipl AAO(Glaucoma)",{"name":64,"role":60,"phone":65,"phoneExt":20,"email":66},{"name":87,"role":88,"phone":20,"phoneExt":20,"email":20},"Donald T Miller, PhD","SUB_INVESTIGATOR",{"name":90,"role":88,"phone":20,"phoneExt":20,"email":20},"Matthew Keller, OD",{"type":92,"investigatorFullName":93,"investigatorTitle":94,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Brett King","Clinical Professor",[96],{"name":97,"class":98},"Alcon Research","INDUSTRY","100657986","phase-4-adaptive-optics-oct-evaluation-of-rhopressas-effects-on-the-retinal-ganglion-cells-in-glaucoma-patients-100657986",false,"NCT07847073","Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients","Inclusion Criteria:\n\n* All subjects will be 18 years of age or older\n* Subjects must be diagnosed with open-angle glaucoma and have had an eye exam within the past year\n* Subjects with glaucoma will have structural (optic nerve and retinal nerve fiber layer) and functional (visual field testing) defects consistent with the diagnosis of glaucoma\n* Subjects will have a corrected acuity of 20\u002F50 or better and be able to fixate\n* Naïve to medication subjects or post washout IOP between 18 and 34 mmHg\n* Spherical equivalent from +3 diopters to -6 diopters, with a cylinder of \\\u003C-3 diopters\n* Subject is willing and able to comply with the protocol requirements and to remain in the study for its full duration, including all scheduled visits and follow-up assessments\n\nExclusion Criteria:\n\n* Subjects with a known intolerance to netarsudil ophthalmic solution\n* Subjects with a known intolerance to, or contraindication for, timolol maleate\n* Any subject whom the investigator determines to be at unacceptable risk for the washout or believes is unlikely to complete the study\n* Subjects with retinal disease or optic neuropathies other than glaucoma that, in the opinion of the investigator, could confound the study assessments or outcome\n* Female subjects who are pregnant, breastfeeding, or of childbearing age who are not sterile or using an acceptable method of contraception during the study","ALL","18 Years",{"count":108,"type":109},13,"ESTIMATED","INTERVENTIONAL",[112],"PHASE4","The purpose of this study is to compare how two FDA-approved eye drops: netarsudil (Rhopressa) and timolol, protect nerve cells in the eye of adults with open-angle glaucoma. Both medications lower pressure inside the eye, but researchers want to learn if Rhopressa is more effective at slowing down or preventing the loss of retinal ganglion cells. These cells are essential for sight because they carry visual signals from the eye to the brain.\n\nParticipants in this study will complete a total of 6 study visits over 12 months:\n\n* Participants will spend 6 months using Rhopressa eye drops and 6 months using Timolol eye drops. The order of the two eye drops will be chosen randomly.\n* At scheduled study visits, researchers will examine participants' eyes and measure eye pressure.\n* Researchers will take detailed pictures of the back of the eye using a specialized high-resolution camera called adaptive optics optical coherence tomography (AO-OCT).\n* Participants will also complete specialized visual field testing to measure eye function.\n\nResearchers will count and track individual nerve cells over time to determine if one medication offers better protection against cell loss than the other.",[115,116],"Open Angle Glaucoma (OAG)","Glaucoma",[118,119,120,121,122,123,124,125],"glaucoma","rhopressa","ganglion cells","optometry","vision","IOP","eye pressure","timolol","2026-09-22",{"date":128,"type":129},"2026-09-29","ACTUAL",{"date":131,"type":109},"2026-10",{"date":133,"type":109},"2028-01",{"name":93,"class":6},1]